Investigational drug · Phase 2
BRII-179
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis B Virus (HBV) Infection, For Treatment of Chronic Hepatitis B Virus Infection.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "BRII-179"
First trial start
2024
Aug 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRII-179", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis B Virus (HBV) Infection
- For Treatment of Chronic Hepatitis B Virus Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BRII-179" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)Pivotal-lookingRecruiting
Brii Biosciences LimitedIndustry
NCT06650852 · 250 participants (planned) · Start Oct 31, 2024 · Primary completion Sep 2028
Drug: BRII-179; BRII-835 (VIR-2218) and 3 more · For: Chronic Hepatitis B Virus (HBV) Infection
Sites: Beijing, China; Guangzhou, China; Shenzhen, China · 14 sites in all
Brii Biosciences LimitedIndustry
NCT06491563 · 150 participants · Start Aug 6, 2024 · Primary completion Aug 5, 2026
Drug: BRII-179; BRII-835 (VIR-2218) and 1 more · For: For Treatment of Chronic Hepatitis B Virus Infection
Sites: Beijing, China; Xiamen, China; Foshan, China · 12 sites in all
Brii Biosciences LimitedIndustry
NCT04749368 · 91 participants · Start Apr 12, 2021 · Primary completion Jul 4, 2023
Drug: BRII-835 (VIR-2218); BRII-179 (VBI-2601) with IFN-α and 1 more · For: Hepatitis B, Chronic
Sites: Kingswood, Australia; Westmead, Australia; Herston, Australia · 28 sites in all
Brii Biosciences LimitedIndustry
NCT05970289 · 86 participants · Start Aug 22, 2023 · Primary completion Jul 16, 2025
Drug: PEG-IFNα; BRII-835 · For: Chronic Hepatitis B Virus Infection
Sites: Kingswood, Australia; Birtinya, Australia; Melbourne, Australia · 28 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Profile and Predictors of Hepatitis B Surface Antigen Seroreversion Following PEG-IFNα with or Without Therapeutic Vaccine BRII-179 or siRNA Elebsiran: A Post Hoc Pooled Analysis of Two Randomized Controlled Trials in Patients with Chronic Hepatitis B Virus Infection.
Gao Z, Lin B, Wong GL, et al. · Vaccines (Basel) 2026
- Therapeutic vaccination for chronic hepatitis B: why most vaccines failed and what may work.
Bertoletti A, Ambike SS, Le Bert N, et al. · Antiviral Res 2026
- Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
Wong GL, Yuen MF, Lin B, et al. · Nat Med 2026
- The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses.
Ji Y, Le Bert N, Lai-Hung Wong G, et al. · Gastroenterology 2025
- Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study.
Ma H, Lim TH, Leerapun A, et al. · JHEP Rep 2021
Also in development for Chronic Hepatitis B Virus (HBV) Infection
- ElebsiranVIR-2218, BRII-835Phase 38 trials
Vir Biotechnology, Inc. · Viral Hepatitis, Hepatitis D, Chronic, Chronic Hepatitis B Virus (HBV) Infection
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.